For people living with Type 1 Diabetes (T1D), keeping blood sugar levels in check is a constant challenge. A new clinical trial at UVA is aiming to simplify diabetes management by testing an ...
Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology firm specializing in regenerative medicine with a market capitalization of approximately $7 million, has revealed promising one-year follow-up ...
19h
Given these compelling results, Creative Medical Technology plans to advance the development of AlloStem (CELZ-201) for the treatment of late-stage Type 2 Diabetes and explore other potential ...
Surrogate measures of insulin resistance, based on the triglyceride-glucose index, can be used to predict the development of ...
Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback